STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...
-- A milestone in pediatric medicine, general pediatricians are now expected to play a more active role in initiating genetic testing -- -- Earlier use of exome and genome testing delivers better ...
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its launch on Aura, Epic’s specialty diagnostics ...
Oct. 28, 2025 3:43 PM ETGeneDx Holdings Corp. (WGS) Stock, WGSWW StockAI-Generated Earnings Calls Insights ...
Claritas Genomics, Inc., announced the launch of its Claritas Clinical Exome, at the Annual Meeting of the American Society of Human Genetics running 10/6 – 10/10 in Baltimore, MD. This novel ...
The optimising EXome PREnatal Sequencing Services (EXPRESS) policy report outlines actions to strengthen clinical implementation of, and further research on, prenatal exome sequencing services in the ...
Hosted on MSN
GeneDx raises 2025 revenue guidance to $428M amid accelerating exome and genome test growth
GeneDx raised full year 2025 total revenue guidance to $425 million to $428 million. Exome and genome revenue guidance was increased to $358 million to $361 million, reflecting 53% to 55% growth for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results